RT Journal Article SR Electronic T1 Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.07.20054767 DO 10.1101/2020.04.07.20054767 A1 Yuan, Xiaolin A1 Yi, Wanrong A1 Liu, Baoyi A1 Tian, Simiao A1 Cao, Fang A1 Wang, Ruoyu A1 Qi, Baiwen A1 Lu, Faqiang A1 Fang, Meiyun A1 Pei, Fuyang A1 Chen, Ming A1 Zhang, Lichuan A1 Zhang, Yong A1 Zhang, Xiuzhi A1 Pan, Zhenyu A1 Zhao, Dewei A1 Yu, Aixi YR 2020 UL http://medrxiv.org/content/early/2020/04/14/2020.04.07.20054767.abstract AB Background As increasing cases of COVID-19 around world, urgent need for effective COVID-19-specific therapeutic drugs is necessary; therefore, we conducted a pilot randomized-controlled study to evaluate the efficacy of 99mTc-MDP for COVID-19 therapeutic treatment.Methods A total of 21 mild patients with COVID-19 were enrolled in this pilot RCT from February 2020 through March 2020, and then were assigned, in a 1:1 ratio, into control (11 patients) and 99mTc-MDP group (10 patients). Patients in the control group received routine treatment and patients assigned to the 99mTc-MDP group received a combination of routine treatment and an administration of 99mTc-MDP injection of 5ml/day. Both of the patients in the control and 99mTc-MDP groups were treated for 7 days with the primary end point of CT-based radiological pulmonary changes during 7-day follow-up.Findings From baseline to the day 7, 8 (80%) of 10 mild patients in the 99mTc-MDP group had a significant radiological improvement in lung and a decline in inflammatory infiltration, whereas only 1 (9.1%) of 11 patients in the control group had a radiological improvement in lung. None of the patients in the 99mTc-MDP group had disease progression from mild to severe, as well as an inflammatory cytokine storm, and 2 mild patients (18.2%) in the control group developed severe. During days 7 through 14, the number of patients with radiological improvement in the 99mTc-MDP group remained consistent, and only 1 additional case (22%) in the control group were reported.Conclusion In this randomized pilot study, 99mTc-MDP had an effective inhibitory effect on the inflammatory disease progression for the therapy of COVID-19, and it can accelerate the absorption of pulmonary inflammation in a short period of time during the process of treatment.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000029431Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be obtained if request.